Virus World
377.6K views | +203 today
Follow
Virus World
Virus World provides a daily blog of the latest news in the Virology field and the COVID-19 pandemic. News on new antiviral drugs, vaccines, diagnostic tests, viral outbreaks, novel viruses and milestone discoveries are curated by expert virologists. Highlighted news include trending and most cited scientific articles in these fields with links to the original publications. Stay up-to-date with the most exciting discoveries in the virus world and the last therapies for COVID-19 without spending hours browsing news and scientific publications. Additional comments by experts on the topics are available in Linkedin (https://www.linkedin.com/in/juanlama/detail/recent-activity/)
Curated by Juan Lama
Your new post is loading...
Scooped by Juan Lama
Scoop.it!

Opinion | The Covid-19 Pandemic Didn’t Have to Be This Way - The New York Times

Opinion | The Covid-19 Pandemic Didn’t Have to Be This Way - The New York Times | Virus World | Scoop.it

Different choices that were available and plausible could have been made at several crucial turning points.  Zeynep Tufekci's Latest:  Dive deep into the internet, technology, politics and society with Zeynep Tufekci's latest column as soon as it’s published. This article is part of Times Opinion’s reflection on the two-year mark of the Covid pandemic. Read more in a note from Alexandra Sifferlin, Opinion’s health and science editor, in our Opinion Today newsletter.

 

We cannot step into the same river twice, the Greek philosopher Heraclitus is said to have observed. We’ve changed, the river has changed. That’s very true, but it doesn’t mean we can’t learn from seeing what other course the river could have flowed. As the pandemic enters its third year, we must consider those moments when the river branched, and nations made choices that affected thousands, millions, of lives. What if China had been open and honest in December 2019? What if the world had reacted as quickly and aggressively in January 2020 as Taiwan did? What if the United States had put appropriate protective measures in place in February 2020, as South Korea did? To examine these questions is to uncover a brutal truth: Much suffering was avoidable, again and again, if different choices that were available and plausible had been made at crucial turning points. By looking at them, and understanding what went wrong, we can hope to avoid similar mistakes in the future.

 

What happened in the first weeks: China covered up the outbreak.

 

Our information about what happened when the coronavirus apparently was first detected in Wuhan, China, in December 2019, remains limited. Reporters working for Western media have been kicked out, and even local citizen journalists who shared information during the early days were jailed. But evidence strongly suggests that China knew the danger long before it told the world the truth. The South China Morning Post, a newspaper owned by a major Chinese company, reported that Chinese officials found cases that date to Nov. 17, 2019. Several Western scientists said colleagues in China had told them of the outbreak by mid-December. Whistleblower doctors reported being silenced from mid-December on. Toward the end of December, hospitals in Wuhan were known to be quarantining sick patients, and medical staff members were falling sick — clear evidence of human-to-human transmission, the first step toward a pandemic. Finally, on Dec. 31, 2019, as rumors were growing, the Wuhan health officials acknowledged 27 cases of an “unexplained pneumonia” caused by a virus, but claimed there was no evidence of “obvious human to human transmission.” The next day, a Chinese state media outlet announced that authorities had disciplined eight people for spreading rumors about the virus, including Dr. Li Wenliang, who had noted that the mystery pneumonia cases resembled SARS and warned colleagues to wear protective gear, and who would later die of Covid. Not until Jan. 20, 2020, did Chinese authorities publicly admit that the virus was clearly passing from person to person. Three days later, they shut down the city of Wuhan. At that point, the virus had had weeks to spread far beyond China’s borders and was beginning to establish outbreaks globally. A pandemic was on its way.....

No comment yet.
Scooped by Juan Lama
Scoop.it!

SARS-CoV-2 Infection Induces Robust Neutralizing Antibody Responses that are Stable for at Least Three Months

SARS-CoV-2 Infection Induces Robust Neutralizing Antibody Responses that are Stable for at Least Three Months | Virus World | Scoop.it

SARS-CoV-2 has caused a global pandemic with millions infected and numerous fatalities. Questions regarding the robustness, functionality and longevity of the antibody response to the virus remain unanswered. Here we report that the vast majority of infected individuals with mild-to-moderate COVID-19 experience robust IgG antibody responses against the viral spike protein, based on a dataset of 19,860 individuals screened at Mount Sinai Health System in New York City.

 

We also show that titers are stable for at least a period approximating three months, and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2. Our data suggests that more than 90% of seroconverters make detectible neutralizing antibody responses and that these titers are stable for at least the near-term future...

 

Preprint available at medRxiv (July 17, 2020):

 https://doi.org/10.1101/2020.07.14.20151126

No comment yet.
Scooped by Juan Lama
Scoop.it!

Coronavirus Vaccines Leap Through Safety Trials — But Which Will Work is Anybody’s Guess

Coronavirus Vaccines Leap Through Safety Trials — But Which Will Work is Anybody’s Guess | Virus World | Scoop.it

Scientists caution against comparing immune responses shown in early-stage trials, and say there might be more than one path to an effective vaccine. When it rains, it pours. In the past few days, scientists working at feverish pace to develop vaccines against the coronavirus have released a flood of data from their first human trials. The results come from phase I and II trials of four promising vaccine candidates, and detail how people respond to the jabs. Because the trials were focused on safety and dosing, the data cannot say whether the vaccines will prevent disease or infection — large-scale efficacy trials are needed for this. But they suggest that the candidate vaccines are broadly safe, and offer the first hints that vaccines can summon immune responses similar to those of people who have been infected with the virus. Crucially, researchers say the data look good enough to merit testing the vaccines in efficacy trials, in which volunteers receive a vaccine or placebo and rates of COVID-19 disease are compared between groups.

 

“I’m really happy that there are quite diverse vaccine strategies going beyond phase I trials,” says Shane Crotty, a vaccine immunologist at the La Jolla Institute for Immunology in California. But scientists caution against over-interpreting the results, and say the data shouldn’t be used to compare the vaccines directly. Eventually, such comparisons will be key to identifying how the vaccines work, or why they fail. The information will also be used to prioritize other vaccines at early stages of development and to design new ones. But none of this is possible yet, because researchers don’t know the precise nature of the immune responses that protect against COVID-19 — and there are likely to be multiple ways to fend off infection. Furthermore, measurements of immune markers made in one lab are difficult to compare with those performed by another team, say scientists. “The data are so early and so preliminary; one thing to avoid is saying one is better at this stage, because we just don’t know,” says Rafi Ahmed, an immunologist at Emory University in Atlanta, Georgia...

No comment yet.